The money is rolling in, but who’s going to get it. The drug, Simponi was just approved by the FDA last month and the lawsuit is still pending on the case where Abbott was sued by Centocor, so you sue me and I’ll sue you. Humira is Abbotts biggest selling drug.
Simponi is the new drug to go on the market from the Johnson and Johnson Centocor Unit and is expected to do well, so this is a big pot of money to haggle over. BD
Get ready for a battle in the rheumatoid arthritis segment. Johnson & Johnson's Centocor unit is prepping for a launch of its new Humira
competitor Simponi, and Abbott Laboratories is not amused. So unamused, in fact, that Abbott slapped J&J with allegations of patent infringement.
All in a day's work for the folks who defend Big Pharma intellectual property, right? Yes and no. Abbott's suit follows up a set of reverse accusations: Last year, Centocor and NYU sued Abbott, saying that they were entitled to patent royalties on Humira. And that case is still pending.
Like Enbrel, Humira, and J&J’s Remicade, the new product works by blocking TNF, or tumor necrosis factor, a germ-fighting protein that also can cause the inflammation found in rheumatoid arthritis patients.
0 comments :
Post a Comment